Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 19/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4371050 | 1.00 | GPR4 (0.73) | GPR4KCNH2HRH3CTSK | |
| Hydrochloric Acid SCHEMBL4374356 | 0.99 | GPR4 (0.72) | GPR4KCNH2HRH3CTSK | |
| Hydrochloric Acid SCHEMBL4374357 | 0.99 | GPR4 (0.72) | GPR4KCNH2HRH3CTSK | |
| SCHEMBL4369325 | 0.90 | GPR4 (0.69) | GPR4KCNH2HRH3CTSK | |
| SCHEMBL4369327 | 0.90 | GPR4 (0.69) | GPR4KCNH2HRH3CTSK | |
| SCHEMBL4375150 | 0.87 | GPR4 (0.70) | GPR4KCNH2HRH3CTSK | |
| SCHEMBL4375152 | 0.87 | GPR4 (0.70) | GPR4KCNH2HRH3CTSK | |
| Hydrochloric Acid SCHEMBL4329780 | 0.87 | GPR4 (0.69) | GPR4KCNH2HRH3CTSK | |
| Hydrochloric Acid SCHEMBL4329777 | 0.87 | GPR4 (0.69) | GPR4KCNH2HRH3CTSK | |
| SCHEMBL4330932 | 0.86 | GPR4 (0.71) | GPR4KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| WO-2009144201-A1 | IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009144201-A1 | IMIDAZOPYRIDINE DERIVATIVES AS GPR4 RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2009-12-03 | — | — | WO | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | TARACIDO IVAN CORNELLA | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216867-A1 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION | GPR4, FABP6, GIPR | GPR4 1/4885KCNH2 4072/4885HRH3 134/4885 |
| US-20090291942-A1 | IMIDAZO PYRIDINE DERIVATIVES | FLT4, UACA, FLT1 | GPR4 119/4885KCNH2 1427/4885HRH3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.